The detection of unknown mutations remains a serious challenge and, despite the expected benefits for the patient's health, a large number of genes are not screened on a routine basis.
INTRODUCTION
The role of genetic screening is becoming increasingly important in cancer diagnosis, prognosis and treatment decisions. Developing fast, reliable and inexpensive methods to detect such mutations is therefore a major challenge for medicine.
Two main strategies are used to search for unknown mutations: direct sequencing and screening. The first strategy is currently considered to be the most reliable, although not totally flawless (Eng, et al., 2001) . More specifically, reliable chemistry and software are prominent points to consider.
The second strategy is a two-step strategy involving preliminary screening for the presence of variants on amplicons, followed by sequencing of only those fragment(s) in which a variation was detected. This dramatically reduces the number of fragments that need to be sequenced.
These screening strategies are mainly based on heteroduplex analysis (HDA), using either a dedicated liquid chromatographic system (Denaturing High Performance Liquid Chromatography, DHPLC) (Spiegelman, et al., 2000) or a real-time PCR machine (High Resolution Melting curve analysis, HRM) (Wittwer, 2009) . During a slow cool-down performed at the end of PCR amplification of a DNA fragment from a heterozygote sample, two homoduplex fragments (corresponding to the normal and mutated allele, respectively) and two heteroduplexes (with mismatched strands due to hybridization of a wild-type strand with a mutant strand) are obtained. The aim of HDA is to check for the presence of heteroduplexes. DHPLC and HRM are widely used in diagnostic laboratories. However, analysis conditions depend on melting domains, and optimization is required for each PCR fragment.
HDA can also be performed by electrophoresis: homoduplexes are separated from heteroduplexes due to differences in electrophoretic mobility. Separations are nowadays F o r P e e r R e v i e w 4 mostly performed by multi-capillary electrophoresis, allowing for high automation, low cost and high throughput, as recently described in a diagnostic validation of Conformation-Sensitive Capillary Electrophoresis (Mattocks, et al.) . A novel HDA method has been recently developed (Houdayer, et al.2010 ). This method, called Enhanced Mismatch Mutation Analysis (EMMA) is based on the use of innovative matrices increasing the electrophoretic mobility differences between homoduplex and heteroduplex DNA (Weber, et al., 2004) .
Sensitivity is further improved by using nucleosides as additives to enhance single-base substitution detection. Nucleosides are expected to interact with mismatched bases of heteroduplexes, thereby increasing mobility differences with homoduplexes (Weber, et al., 2006) . Moreover, this method, in combination with adapted semiquantitative PCR conditions, can be used to simultaneously detect point mutations and large-scale rearrangement in a single run (Weber, et al., 2007) . This feature, combined with the use of a single set of separation conditions for all fragments and with the multiplexing capability of the method, leads to a considerable simplification and cost reduction compared to previous methods.
The use of EMMA for fast screening of BRCA1 and BRCA2 point mutations and large rearrangements is described below. Constitutional mutations of the BRCA1 [MIM 113705] and BRCA2 [MIM 600185] genes are associated with a risk of hereditary breast and ovarian cancer (HBOC). It is essential to identify BRCA1/2 mutations to provide appropriate counseling to patients and relatives, but this represents a challenging and time-consuming task, as the vast majority of mutations are unique and spread over the entire coding sequence.
In this paper, we report the results of BRCA1 and BRCA2 screening for point mutations and large rearrangements in 1,525 unrelated patients (372 for the validation step and 1,153 in routine diagnosis), and discuss the performance of this new strategy. 
Patients
Genetic testing for BRCA1 and BRCA2 was proposed to women based on individual and/or family history (herein defined as index cases i.e. the first family member in whom complete BRCA1/2 gene screening was performed). Individual inclusion criteria included: i) breast adenocarcinoma before the age of 36, ii) medullary adenocarcinoma without age limitation, iii) breast adenocarcinoma and ovarian cancer. Male breast cancer was also considered for genetic testing. Family history was defined as either i) 3 breast cancer cases in first-or second-degree relatives in the same lineage, ii) 2 breast cancer cases in first-or second-degree relatives (with a transmitting male), with one cancer before the age of 40 or one cancer before 50 and the other before 70 iii) 1 breast cancer case and one first-or second-degree relative (with a transmitting male) with ovarian cancer. During the course of this study, and in line with French recommendations, inclusion criteria were recently extended to women with isolated ovarian adenocarcinoma before the age of 70 (http://www.e-cancer.fr/lessoins/oncogenetique). A consecutive series of 1,525 ascertained cases, mostly of Caucasian descent, were studied. All patients attended a visit with a geneticist and a genetic counselor in a family cancer clinic, mostly at the Institut Curie, Paris, France. Patients gave their informed consent for BRCA1/2 gene analyses. .
Nucleic acid extraction
For mutation scanning purposes, DNA was extracted from 2 ml whole blood samples collected on EDTA using a modified perchlorate/chloroform procedure (first 465 samples), as F o r P e e r R e v i e w 6 previously described (Johns and Paulus-Thomas, 1989) , or the NucleoSpin blood L kit from Macherey Nagel (following 849 samples) or the Quickgene 610-L automated system from FujiFilm (last 211 samples) according to the manufacturer's instructions. Three different extraction procedures were used during this study in the context of a constant effort to reduce the time and labor involved, finally leading to the semi-automated solution from FujiFilm.
DNAs were calibrated to 50 ng/µl by UV spectrophotometric assay (Nanodrop). Absorbance ratios (260/280) and (260/230) had to be in the 1.8-2.0 and 2.0-2.2 ranges, respectively.
Enhanced Mismatch Mutation Analysis (EMMA)
Primer design. Primers were purchased from Fluigent, Paris, France. BRCA1 and BRCA2 coding sequences were divided into 81 amplicons analyzed in 24 multiplex PCRs including one internal control for large-scale rearrangement analysis (Primer sequences are available from Fluigent). Primers were designed to include flanking intronic sequences containing recognized splice sites and avoiding known polymorphism to prevent mispriming.
Due to the well-known limitations of capillary electrophoresis (Rozycka, et al., 2000) and topological effects (Weber, et al., 2004) , false-negatives can occur in the 70bp from both extremities of the amplicon. As a result, larger and overlapping amplicons were designed so that the sequence of interest always fell outside these 70bp in at least one amplicon (Weber, et al., 2006) . One primer of each pair was labeled with 6-carboxyfluorescein (6-FAM). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   8 www.hgvs.org/mutnomen). The initiation codon is codon 1. Electrophoregrams were examined and scored by two operators. All mutations were confirmed on a second blood or buccal swab sample.
Large rearrangements. EMMA and quantitative multiplex PCR of short fluorescent fragments (QMPSF) were both used to screen for BRCA1 and BRCA2 rearrangements because automated profile analysis was easier with QMPSF (see below). QMPSF was used as previously described (Casilli, et al., 2006) . All rearrangements were confirmed on a second blood sample and using another technique e.g. long range PCR, transcript analysis or a dedicated array-CGH (Rouleau, et al., 2007) . Spurious single-exon deletions due to mispriming were therefore unambiguously excluded.
Unknown Variants (UVs) interpretation
In silico analysis. Unfortunately, one half of the variations observed in the BRCA1/2 genes are UVs (Hofstra, et al., 2008) , making biological and clinical interpretation a challenging task and consequently leading to clinically difficult situations. To facilitate subsequent genetic counseling, all identified UVs were submitted to in silico analysis using Alamut (Interactive Biosoftware), a decision-support system for mutation interpretation that integrates a splice prediction module. Apart from the impact on splicing, unknown variants were also analyzed for their putative "protein-based" impact by cross-species and Grantham score (Grantham, 1974) comparisons, and were then scored using an in-house model (Supp. cosegregation analyses or functional studies) above 12. In such cases, the clinical context was also thoroughly discussed with the clinical geneticist. Based on previous knowledge (Houdayer, et al., 2008) , defects were defined as a minimum 10% decrease of the wild-type score. Emergence of a cryptic splice site was considered significant and worthy of RNA study when it scored at least 50% of the corresponding wildtype score. ESEs were not considered for routine purposes.
RNA was extracted from lymphoblastoid cell lines with and without puromycin treatment.
RNA was reverse-transcribed and the BRCA1/2 coding sequence surrounding the region of interest was amplified (primer sequences available on request).
Amplicons were purified and sequenced in both directions using the BigDye Terminator Cycle Sequencing V1.1 Ready Reaction kit (Applied Biosystems) with incorporation of the PCR oligonucleotides as extension primers, followed by electrophoresis in an ABI PRISM 3130XL Genetic Analyzer with analysis using the Collection and Sequence Analysis software package (Applied Biosystems). Normal controls were always included in these experiments. (Weber, et al., 2004; Weber, et al., 2006) [and author's unpublished data]. A series of blind studies were then performed using DHPLC and QMPSF as reference techniques for point mutation and large rearrangement screening, respectively. DHPLC was chosen as a reference because it is considered to be the gold standard for mutation prescreening with more than 1,000 PubMed references [http://www.ncbi.nlm.nih.gov/sites/entrez]. Moreover, our laboratory has an extensive experience with this technique, with more than 4,000 patients screened for BRCA1/2 and RB1 point mutations Wagner, et al., 1999) and, more recently, large-scale rearrangements using the DHPLC-derived technique called MP/LC .
The blind studies involved a total of 372 patients. Two hundred and seventy nine cases were first screened on BRCA1 by Fluigent in their mutation detection facility, and 93 cases were then screened on both BRCA1 and BRCA2 in our laboratory. PCR conditions and analyses were as described above. An equivalent sensitivity was demonstrated, as 127 variations (excluding polymorphisms) were found with both techniques. Actually, one variation was missed by EMMA (BRCA2, c.9364G>A/p.Ala3122Thr), but another variation missed by DHPLC was detected by EMMA (BRCA1, c.2311T>C/p.Leu771Leu). of the relative proportion of a given fragment in the unknown sample with respect to a normal control. In order to compare two fragments amplified in two different tubes, peak intensities and areas are normalized to a non-mutated DNA fragment used as an internal control.
Fluorescence intensities were then normalized by adjusting the peaks and areas obtained for the control amplicons to the same level and the yield of each amplicon in the various samples was evaluated. As some profiles exhibit variations due to polymorphisms, rare variants and mutations, Emmalys analyzes variant and non-variant profiles separately and deletions are detected by a 50% decrease in peak intensity and area, while duplications are detected by a 1.5-increase in profile area. Firstly, a 30-sample dedicated large rearrangement panel was blindly tested using this procedure. This panel included 20 BRCA1 large rearrangements (deletions and duplications) and 10 normal controls. All samples were correctly scored. The second step of the validation consisted of identification of 3 large rearrangements present in the 372 patients. Two deletions encompassing exons 15 and 16 and 13 to 15, respectively, were correctly detected. The third deletion, a deletion of BRCA1 promoter, was not detected because the current EMMA primer panel does not explore this part of the gene (which is covered by our QMPSF assay).
Interpretation of polymorphisms according to their profiles.
One of the main challenges with prescreening methods is the correct identification of polymorphisms. This does not constitute an issue for genes with a very low polymorphic content such as RB1 but is a major hurdle for BRCA genes, which exhibit a large number of polymorphisms throughout their sequence. In this case, the advantages of prescreening methods are lost if each variant peak has to be sequenced (Mattocks, et al. 2010 ). The situation becomes much simpler if the method allows correct recognition of polymorphisms according to their profile. This requires a high profile specificity and reproducibility. Profiles Reproducibility was evaluated within series and between series, by superimposition of profiles from the same variant. Profiles matched very accurately ( Figures 1A, B ). A high profile specificity was also observed, as illustrated e.g. Figure 2 illustrating 2 polymorphic profiles and the co-occurrence of these two polymorphisms in the same patient.
Polymorphisms were consequently expected to be identified from their variant profile. To validate this hypothesis, all variant profiles interpreted as polymorphisms in this series of 93 patients were sequenced (for a total of 1,200 sequences), and sequencing results were compared to EMMA interpretation. In every case, the expected polymorphism was found and no extra polymorphism was found in the remaining variant profiles, corresponding to a sensitivity and specificity of 100% in this series. To ensure correct interpretation, polymorphisms should be interpreted together and compared between each other instead of being compared to a normal control.
Mutations Identified in Routine Screening
DNAs from 1,153 hereditary breast/ovarian cancer patients were subjected to routine EMMA screening followed by sequencing of variant fragments. An average of 10 to 15% of PCRs had to be re-amplified due to low signal-to-noise ratio (see discussion section) and 3% of variant amplicons were sequenced. The 137 mutations found are reported in Supp. Tables S1A-B. The overall mutational detection rate according to our inclusion criteria was 11.9%
i.e. 6% and 5.9% on BRCA1 and BRCA2, respectively. The unknown variant detection rate (Supp . Table S2 ) was 33.5% i.e. higher than previously reported because of the length of the intronic sequences analyzed that includes a 70bp "safe zone" (see "primer design"). This increased number of intronic UVs may represent a drawback of the design which is why (Plon, et al., 2008) .
Throughput
Patients were initially analyzed by series of 96, according to the same organization as previously used with DHPLC. Following a learning curve period, series of 30 patients were subsequently analyzed. It now takes seven working days for complete BRCA1/2 screening in 30 patients by one technician (excluding DNA extraction and sequencing). 
EMMA
This is the first report of a large-scale study using EMMA, some aspects of this methodology therefore need to be discussed. Capillary electrophoresis was developed as an attractive strategy for mutation detection in the early 1990's (Khrapko, et al., 1994) . However, its broad diffusion was hampered by design constraints and lack of sensitivity (Rozycka, et al., 2000) . The recently described Heteroduplex Analysis by Capillary Array Electrophoresis (Perez-Cabornero, et al., 2009) , also called Conformation-Sensitive Capillary Electrophoresis (CSCE) (Mattocks, et al. 2010 ) represents a real improvement, but it also presents certain disadvantages. It uses a home-made polymer recipe that does not allow batch-to-batch reproducibility. Consequently, all fragments with altered peak patterns need to be sequenced, dramatically increasing the amount of sequencing needed for genes such as BRCA1/2, which involve frequent polymorphisms; large rearrangements cannot be detected and mutational screening must be completed by another method.. EMMA retains the simplicity and throughput of CSCE, but as a result of a series of additional developmentscomprising industrialized ready-to-use separation matrix and specific software, it overcomes the above limitations. It allows easy and reliable recognition of polymorphisms according to their profile, and it is the first technique able to detect large rearrangements and point mutations in a single run (Weber, et al., 2007) .
. Some technical remarks and guidelines for implementation and use, based on our experience, are listed below. Regarding DNA extraction, 3 different procedures were used during the course of the study (see Materials and Methods" section) without any incidence on data quality. Due to its high sensitivity, in order to take full advantage of the potential of the technique for direct polymorphism identification, specific PCR amplifications must be used since nonspecific products could generate shouldering for a wild-type sample, making the profile difficult to interpret. Nonspecific products may also be generated by primer degradation with time, but this is easily detected because profiles lose their reproducibility.
Capillary electrophoresis always involves slight run-to-run and capillary-to-capillary mobility shifts, so it is therefore important to compare peaks after correct peak alignment, which can be tricky with conventional software in the case of complex profiles. The Emmalys software appeared to effectively deal with this difficulty, as suggested by the robustness of polymorphism analysis.
Strikingly, heteroduplexes could be either slower or faster than homoduplexes and no rule was found that could link one type of nucleotide substitution to one type of mobility difference or profile shape. Electrophoretic mobility does not only depend on the mismatch bases, but also on the local sequence environment of this mismatch, since distortions of the DNA helix at one base pair are propagated to the neighboring bases (Weber, et al., 2004) . As a consequence of the above, a heteroduplex can exceptionally comigrate with the peak corresponding to the following/preceding peak in the multiplex electrophoregram. Therefore, if an amplicon from a patient shows an abnormal profile, but does not show any variation on sequencing, it could indicate that the altered amplicon is actually a neighboring amplicon.
This can be easily confirmed by observing the result of large rearrangement analysis, which should in turn mimic a deletion on the neighboring peak. Similarly, the quantitative analysis Finally, to ensure reliable and easy interpretation of polymorphisms, it is recommended to work on series of 30 samples or more. Below this range, it may prove difficult to correctly interpret polymorphism profiles because of an insufficient number of reference profiles.
Distinct injection protocols are available to ensure optimum results (EMMA high-low). In a first, "low" injection mode, samples are injected for 10s -20s at 1kV -4kV then electrophoresed at 15kV for 45 min. This injection mode has a sufficiently low consumption to allow a second run to be performed from the same sample using a "higher injection" protocol, in the event of occasional unexpected problems (missed injection, capillary failure, microbubble, etc). All of these "tricks", recommendations and checkpoints are summarized in the Analysis Pipeline, Figure 3 .
The viscosity of EMMA separation medium is higher than that of other solutions conventionally used in ABI instruments. This requires certain modifications of the capillary filling and apparatus operation sequences (provided by Fluigent), compared to standard procedures. For instance, this involves longer array filling time, capillary rinsing with buffer every 100 runs, and capillary array exchange every 400 runs. Replacing EMMA buffer 1x daily is also recommended to avoid loss of resolution. System performance and integrity should be checked once a week using a control sample (a 4-plex PCR with variant profiles for each peak, available from Fluigent). As for any heteroduplex analysis, homozygous mutations cannot be detected by EMMA on the direct sample, but this can be circumvented by adding a wild-type DNA in the sample to force heteroduplex formation, as previously demonstrated with DHPLC (Ferec, et al., 2004) . In addition to the above precautions and issues, which require the level of care typically required by molecular diagnosis, EMMA uses standard and well-known sequencers and a set of ready-to-use reagents, thereby facilitating upgrading to this new technology.
The cost of consumable items used to screen BRCA1 and BRCA2 by EMMA is estimated to be less than 100 euros per patient (based on price list). This estimation excluded the costs of DNA extraction and sequencing, purchase of the sequencer, instrument depreciation and labor. The markedly reduced need for downstream sequencing (typically 3%), as a result of polymorphism identification, is also a factor for cost reduction (Sevilla, et al., 2002) .
This technology allows a high throughput and our laboratory now generates close to 9000 amplicons per month for diagnostic purposes; it should be stressed that the management of such a large volume of data requires a robust data management system. We have therefore The advantages of EMMA compared to our previous DHPLC-based strategy are obvious: they comprise a single condition for amplification and run, a higher throughput and lower costs (lab technician time decreased to one quarter and overall cost decreased to one third, compared to DHPLC in our hands). The simultaneous detection of point mutations and large rearrangements is another advantage. However promoter regions are not covered and this must be taken into account, since deletions of the promoter regions are a probably rare but significant cause of HBOC (Brown, et al., 2002; Caux-Moncoutier, et al., 2009 ). Although technical performance was acceptable, the complexity of the currently available Emmalys interface prevents routine use of large rearrangement detection. On the other hand, Emmalys was found to be robust and user-friendly for point mutation detection. (Coulet, et al., 2010 ; Rouleau, et al., 2009 ). Its main advantage over EMMA is the absence of post-PCR manipulation. However, based on the recent literature, HRM appears to have a number of drawbacks (which are overcome by EMMA), notably:
i) its sensitivity depends on the nucleotide composition of the amplicon (melting domains).
HRM diagnostic guidelines for BRCA1 screening recommend extreme caution when analyzing high-GC, low-GC contents and fragments containing many different variants (van der Stoep, et al., 2009; Wittwer, 2009) ii) interpretation of polymorphisms according to their profile would need probes or sequence analysis to exclude the presence of a mutation with an identical melt profile (Nguyen-Dumont, et al., 2009 ).
Spectrum of Mutations
The mutation detection rate in BRCA genes largely depends on the patient inclusion criteria and selecting high-risk patients from breast and ovarian families would provide the geneticist with a higher mutation detection rate than including patients based exclusively on their personal history. That being said, the sensitivity of EMMA was 11.9% in our series of 1,153 patients, which is in line with expectations with regards to patient inclusions and compared to previous results using DHPLC as well as data from French laboratories (http://www.e-cancer.fr).
Considering the mutational spectrum, the recurrent so-called Ashkenazim mutations (BRCA1 68_69del, 5266dupC and BRCA2 5946delT) represented 9.5% of our identified mutations, which is why prescreening for these 3 mutations is proposed during genetic counseling to patients reporting an Eastern European origin. Apart from these mutations, we did not observe a larger panel of recurrent mutations which would justify a first-line screening procedure, as described in other populations (Revillion, et al., 2004) . Few deleterious inframe/missenses mutations were found but this could actually reflect an interpretation bias in view of the fact that 386 unknown variants were detected (detection rate 33.5%). In other words, these 386 variants no doubt included deleterious neutral/missense/intronic mutations, which is why scoring variants to highlight prominent candidates for future collaborative studies is of special relevance for optimization of molecular diagnosis. There is considerable debate about the usefulness of large rearrangement screening in BRCA genes. The main argument against such screening, is that the time and efforts needed for such screening might be used more efficiently by screening more patients but for point mutations only. Previous reports (Engert, et al., 2008; Mazoyer, 2005) suggested that large rearrangements accounted for an average of 10% of the BRCA1 mutational spectrum. Although our present results are lower (5.8%), we can confidently confirm that it is worth searching for BRCA1 large rearrangements in genetic diagnosis, regardless of the patient's family history. The situation is less clear for BRCA2 because previous studies, including those from our team (Casilli, et al., 2006; Tournier, et al., 2004) , were based on smaller series and selected high-risk families (Agata, et al., 2005; Engert, et al., 2008; Woodward, et al., 2005) . These studies led to the overall conclusion that BRCA2 genomic rearrangements are worth investigating in high-risk families. This does not mean that these mutations are associated with a higher risk, but that due to the very low contribution of large rearrangements in the BRCA2 mutational spectrum, the search for these mutations should be limited to patients with a severe family history associated with a high BRCA2 mutation detection rate. Two BRCA2 large rearrangements, one complete deletion and one duplication of exons 19, 20 ( Figure 4) were found in the present series of 1,153 consecutive patients. The deletion was found in a young breast cancer patient with no family history i.e. a low-risk case. Conversely, the duplication was found in a high-risk family: the (Parmigiani, et al., 1998) and 57.9%(12.1% for BRCA1 and 45.8% for BRCA2) according to the BOADICEA model (Antoniou, et al., 2008) . Interestingly, her older affected sister was found to be negative using a combination of direct sequencing for BRCA1/2 and a limited 5-site rearrangement panel for BRCA1(Comprehensive BRACAnalysis®, Myriad® Genetics laboratories Inc. Salt Lake City, USA). Following identification of the BRCA2 duplication in our index case, genetic testing and appropriate genetic counseling were made available to the relatives e.g. 6 unaffected females (at least) and the affected sister. As expected, the affected sister carried the BRCA2 duplication. More generally, and as this kind of mutation might also be found in low-risk situations, this study argues in favor of methods allowing simultaneous and convenient detection of point mutations and large rearrangements to enable clinical geneticists to meet the constraints of routine genetic testing.
General conclusions and perspectives
The main advantages of EMMA are that it provides a marked increase of throughput (or cost reduction at a given throughput) compared to DHPLC and is based on standard sequencers routinely used in laboratories. It can therefore be easily implemented in laboratories familiar with capillary electrophoresis, and allows screening and sequencing on the same platform. Due to its flexibility, EMMA could also be used for rapid BRCA screening of a subset of patients e.g. before poly(ADP-ribose) polymerase inhibitor treatment Tutt, et al. 2010) . EMMA obviously cannot compete with SOLiD in terms of throughput, but indeed only a small number of diagnostic laboratories actually need such amazing sequencing capacities.
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